Semax (ACTH 4-10 Analog) Evidence Grade: A-
Semax is a synthetic heptapeptide consisting of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro) with a stabilizing Pro-Gly-Pro C-terminal tripeptide extension. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a nootropic and neuroprotective agent. Semax is approved for clinical use in Russia for cognitive disorders, stroke recovery, and optic nerve diseases.
Despite being derived from the ACTH sequence, Semax has no adrenocortical hormonal activity, as the steroidogenic region of ACTH (residues 1-3) is absent. Instead, Semax retains and enhances the neurotrophic properties of the ACTH(4-10) fragment, primarily through upregulation of brain-derived neurotrophic factor (BDNF) and modulation of dopaminergic and serotonergic systems.
Table of Contents
Overview & Introduction
Semax was developed over two decades of research at the Institute of Molecular Genetics, Russian Academy of Sciences, under the leadership of Nikolai Myasoedov. The peptide design strategy involved taking the ACTH(4-10) fragment, known to enhance memory and attention in animal models without hormonal activity, and adding a C-terminal Pro-Gly-Pro tripeptide extension to increase enzymatic stability and biological half-life.
The resulting heptapeptide demonstrates potent nootropic (cognitive-enhancing), neuroprotective, and neurotrophic properties in both animal models and human clinical studies. Semax increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus and cortex, enhances synaptic plasticity, modulates dopaminergic and serotonergic neurotransmission, and protects neurons from ischemic and oxidative damage.
Semax received regulatory approval in Russia in 1994 and has been used clinically for over 30 years. It is available as a 0.1% nasal spray for cognitive enhancement and as a 1% solution for acute neurological conditions including ischemic stroke and optic nerve atrophy. The intranasal route provides direct access to the central nervous system via olfactory and trigeminal nerve pathways, bypassing the blood-brain barrier.
In the international research community, Semax has gained attention as one of the few peptide nootropics with substantial clinical evidence supporting its cognitive enhancement and neuroprotective claims. Its favorable safety profile, non-addictive nature, and absence of hormonal effects distinguish it from many other cognitive-enhancing compounds.
History & Discovery
ACTH fragment research. Studies at the Institute of Molecular Genetics established that the ACTH(4-10) fragment retains the neurotrophic and cognitive effects of full-length ACTH without adrenocortical activity. This fragment became the template for Semax development.
Semax synthesis and preclinical studies. The Pro-Gly-Pro extension was added to stabilize the ACTH(4-10) sequence. Extensive preclinical studies confirmed enhanced nootropic activity, neuroprotective effects, and improved pharmacokinetic properties.
Russian regulatory approval. Semax received approval in Russia as a nootropic agent. The 0.1% nasal solution was indicated for cognitive enhancement, attention disorders, and memory improvement.
Stroke and neuroprotection studies. Clinical trials demonstrated Semax's efficacy in acute ischemic stroke, leading to approval of the 1% concentration for neurological emergencies. Studies showed reduced infarct volume and improved neurological outcomes.
International research expansion. Semax gained global research interest. Studies explored applications in ADHD, depression, anxiety, chronic pain, and neurodegenerative diseases. Modified versions (N-Acetyl Semax) were developed for improved potency.
Mechanism of Action
Semax strongly upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in the hippocampus, cortex, and basal forebrain. BDNF promotes synaptic plasticity, long-term potentiation (LTP), neurogenesis, and neuronal survival. NGF supports cholinergic neuron maintenance. This neurotrophic mechanism underlies Semax's cognitive enhancement and neuroprotective effects.
Semax modulates dopamine turnover in the striatum and prefrontal cortex, enhancing dopaminergic neurotransmission without causing dopamine depletion. This contributes to improved attention, focus, motivation, and working memory. Unlike stimulant drugs, Semax's dopaminergic effects are modulatory rather than directly agonistic, reducing addiction potential.
Semax influences serotonin metabolism and receptor sensitivity, contributing to anxiolytic and mood-stabilizing effects. The serotonergic modulation, combined with BDNF upregulation, provides the mechanistic basis for observed antidepressant-like effects in animal models and clinical observations.
In ischemic stroke models, Semax reduces inflammatory cytokine expression (TNF-alpha, IL-1beta) in brain tissue, limits microglial activation, and enhances antioxidant enzyme activity. These neuroprotective mechanisms reduce secondary brain injury following ischemic events and may be relevant to chronic neuroinflammatory conditions.
Research Applications
Cognitive Enhancement
Semax's primary application. Enhances memory consolidation, attention, information processing speed, and learning capacity in both healthy subjects and those with cognitive impairment.
Stroke Recovery
Acute ischemic stroke treatment at 1% concentration (Russia). Reduces infarct volume, improves neurological recovery, and enhances functional outcomes when administered within the acute treatment window.
ADHD Research
Studied for attention deficit hyperactivity disorder, with clinical evidence suggesting improvement in attention, impulsivity, and hyperactivity measures.
Optic Nerve Diseases
Approved in Russia for optic nerve atrophy. Promotes optic nerve regeneration and improves visual function through neurotrophic mechanisms.
Neuroprotection & Neurodegeneration
Research explores Semax's potential in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions through its BDNF/NGF upregulation and anti-inflammatory mechanisms.
Clinical Evidence
BDNF Upregulation and Neurotrophic Mechanism
Dolotov et al. (2006) demonstrated that Semax significantly increases BDNF mRNA expression in the rat hippocampus and cortex following intranasal administration. The BDNF upregulation was dose-dependent and persisted for several hours after administration, providing the molecular basis for Semax's cognitive enhancement and neuroprotective effects.
PMID: 16996037
Ischemic Stroke Clinical Trial
Gusev et al. (1997) reported a controlled clinical trial of Semax (1% intranasal) in acute ischemic stroke patients. Treatment initiated within 6 hours of symptom onset produced significant improvements in neurological deficit scores, cognitive function recovery, and overall clinical outcomes compared to standard therapy alone. The study established Semax as an adjunctive neuroprotective treatment for acute stroke.
PMID: 9273545
Cognitive Enhancement in Healthy Volunteers
Eremin et al. (2005) studied Semax's effects on attention and memory in healthy volunteers using psychometric testing batteries. Intranasal Semax (0.1%) produced statistically significant improvements in selective attention, short-term memory, and cognitive flexibility compared to placebo, with effects apparent within 30 minutes of administration.
PMID: 16240847
Gene Expression Profiling
Agapova et al. (2007) profiled Semax-induced gene expression changes in the rat brain using microarray analysis. The study identified upregulation of 24 genes involved in neurotrophic signaling, synaptic plasticity, and neuroprotection, providing a comprehensive molecular snapshot of Semax's mechanism of action at the transcriptomic level.
PMID: 17195926
Dosing Protocols (Research Context)
Note: Semax is approved in Russia but not FDA/EMA-approved. Dosing information reflects published Russian clinical and research protocols.
| Form | Dose | Frequency |
|---|---|---|
| 0.1% Nasal Solution | 200-600 mcg/day (2-3 drops per nostril) | 2-3 times daily |
| 1% Nasal Solution | 2-6 mg/day (acute neurology) | 3-4 times daily |
| Subcutaneous Injection | 100-500 mcg | 1-2 times daily |
Standard cognitive enhancement protocols use the 0.1% solution for 10-14 days. Acute neurological protocols use the 1% concentration for 5-10 days. Cycles can be repeated after 1-2 week washout periods.
Administration & Reconstitution
Nasal Spray (Primary Route)
Semax nasal solutions are pre-mixed and ready to use. Tilt head slightly back, insert nozzle into nostril, and deliver prescribed number of drops. Alternate nostrils between doses. The intranasal route provides rapid CNS access within minutes.
Injectable Reconstitution
| Vial Size | BAC Water | Concentration |
|---|---|---|
| 5 mg | 2.5 mL | 2 mg/mL |
- Reconstitute gently with bacteriostatic water
- Inject subcutaneously using insulin syringes
- Nasal route preferred for CNS-targeted effects
Side Effects & Safety Profile
Semax has an exceptionally clean safety profile based on 30+ years of clinical use in Russia, with no reported serious adverse events, no addiction potential, and no withdrawal symptoms upon discontinuation.
Rare/Mild
- Mild nasal irritation (intranasal route)
- Transient dizziness (uncommon)
- Mild headache (rare)
Notable Safety Features
- No hormonal/adrenocortical effects
- No addiction or tolerance development
- No withdrawal syndrome
- No sedation or psychomotor impairment
Stacking & Combinations
Semax + Selank
The classic Russian nootropic combination. Selank provides anxiolytic and mood-stabilizing effects while Semax delivers cognitive enhancement and BDNF upregulation. The combination addresses both cognitive performance and emotional resilience.
Semax + Epithalon
For neuroprotective anti-aging: Semax delivers direct neuroprotection and cognitive support while Epithalon provides telomerase activation and pineal gland restoration. Targets brain health from both functional and cellular aging perspectives.
Semax + BPC-157
For CNS recovery research: Semax's neurotrophic BDNF/NGF pathway and BPC-157's dopaminergic/serotonergic modulation may complement each other in neurological recovery models.
Storage & Stability
| Form | Conditions | Duration |
|---|---|---|
| Nasal Solution (sealed) | Refrigerated (2-8°C) | Until expiry |
| Nasal Solution (opened) | Refrigerated | 30 days |
| Lyophilized Powder | Refrigerated | 24+ months |
| Reconstituted | Refrigerated | 21 days |
Regulatory Status
- Russia: Approved prescription nootropic and neuroprotective agent (since 1994). Available as 0.1% and 1% nasal solutions.
- United States: Not FDA-approved. Available as research peptide.
- European Union: Not EMA-approved. Research chemical.
- WADA: Not currently on the Prohibited List.
Frequently Asked Questions
Is Semax approved for medical use anywhere?
Does Semax have hormonal side effects like ACTH?
How is Semax administered?
What is the difference between Semax and N-Acetyl Semax?
References
- Dolotov OV, et al. "Semax, an analog of ACTH(4-10), regulates expression of BDNF and trkB in the rat hippocampus." Dokl Biol Sci. 2006;408:310-312. PMID: 16996037
- Gusev EI, et al. "Efficacy of semax in acute period of hemispheric ischemic stroke." Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 9273545
- Eremin KO, et al. "Semax improves attention processes." Bull Exp Biol Med. 2005;140(5):586-588. PMID: 16240847
- Agapova TY, et al. "Effect of Semax on the expression of genes in brain." Dokl Biol Sci. 2007;414(1):213-216. PMID: 17195926
Related Pages
Concise compound overview
Step-by-step research protocol
Anxiolytic peptide partner
Anti-aging combination
Medical Disclaimer: This article is for educational and research purposes only. Semax is not FDA-approved. Consult a healthcare professional. See our full Medical Disclaimer.
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.